Reminders

Changing Life Sciences Value Chain

Archives for October 2009 « Recent Articles

OfflinePhoto of Dr. Alan S. Louie

A Changing FDA – Barkless and De-Clawed No More?

By Dr. Alan S. Louie

For many years, the FDA was not unlike the Federal Reserve in its ability to only primarily exert a single weapon.  In the Fed’s case, it was its ability to modify the interest rate that banks charge each other.  In the FDA’s case, it is the ability to approve or reject a new drug application.  While this is clearly an oversimplification of both the Fed and the FDA, it has been the general public’s perception of both.  Other than Vioxx (which I would highlight as the ha


OfflinePhoto of Eric Newmark

Oracle Set To Enter Drug Pedigree Market

By Eric Newmark

Implementing a drug pedigree system in the USA has been a painfully slow process that has thus far produced marginal results at best. While the creation of a single national standard is the logical end game to this industry initiative, lack of progress has forced individual states to step-up and implement their own regulations to help ensure the safety of their citizens. As a result, a quickly growing patchwork of varying rules are popping up across the country under which pharmaceutical companies must comp


OfflinePhoto of Dr. Alan S. Louie

Recent announcements regarding progress in the development of vaccine-based therapeutics for nicotine and cocaine addiction (Nabi Pharmaceuticals NicVAX and Yale School of Medicine experimental cocaine vaccine research respectively), AIDS (Thailand Ministry of Public Health and the U.S. Army), and cancer (multiple programs) are adding both new directions and new opportunities for companies to help address the ills of mankind.  The shift beyond the traditionally low margin flu vaccine market to higher v


OfflinePhoto of Eric Newmark

KPO - Pharma's Next Outsourcing Move

By Eric Newmark

After several years of cost cutting efforts within the pharmaceutical industry,  the "leave no stone unturned" approach is beginning to run out of rocks to look under. While opportunities do still exist (ie. Revenue leakage), much has already been done. Most sales forces have been trimmed significantly, supply chain and manufacturing operations have been significantly leaned, and IT consolidation and rationalization efforts are well underway. As a result, many pharma's are looking for the next frontier



Viewed 699,541 times